MMS Holdings alternatives
Companies similar to MMS Holdings on cro.directory, ranked by shared capabilities and locations focusing on Radiopharmaceutical, Vaccine, Biologics (Other), and Biologics (Monoclonal Antibodies). Below are the top 10 cros with overlapping structured profile data.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Shares EU EMA Regulatory Strategy, US FDA Regulatory Strategy, Regulatory Affairs, and Pharmacovigilance & Drug Safety.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Shares EU EMA Regulatory Strategy, US FDA Regulatory Strategy, Regulatory Affairs, and Medical Writing.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Shares US FDA Regulatory Strategy, Regulatory Affairs, Medical Writing, and Phase IV / Post-Marketing.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
How we pick similar companies: alternatives similarity uses shared services, modalities, locations, and site-specific capability fields — not sponsorship. Missing fields stay blank. Data comes from structured directory profiles.
← Back to MMS Holdings profile
Interactive comparison
Lock shared capabilities to filter peers. Locked views are not indexed — the canonical page stays unlocked.
Capability locks
- Accelsiors
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
- Fortrea
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
- Citeline
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
- Parexel
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
- Genelife Clinical Research Pvt. Ltd.
Shares EU EMA Regulatory Strategy, US FDA Regulatory Strategy, Regulatory Affairs, and Pharmacovigilance & Drug Safety.
- Novotech
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
- Clario
Shares EU EMA Regulatory Strategy, US FDA Regulatory Strategy, Regulatory Affairs, and Medical Writing.
- IQVIA
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
- Innovate Research
Shares US FDA Regulatory Strategy, Regulatory Affairs, Medical Writing, and Phase IV / Post-Marketing.
- PPD
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Markdown mirror: /alternatives/mmsholdings.md